Your Class IIa Device Is Now Class IIb—And No One Told You

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This is not an isolated case. I see it in audit after audit. Devices that were comfortably sitting in Class I or IIa under the MDD are now moving up under MDR. The problem is not just the additional regulatory burden. The problem is that many manufacturers do not realize the shift until it is too late. They submit files built on the wrong foundation, and the deficiency cascade begins.

Upclassification under MDR is real, systematic, and predictable. Yet it keeps catching teams off guard.

Why Classification Changed Under MDR

The classification rules in MDR Annex VIII are not the same as the ones in MDD Annex IX. The structure looks similar at first glance. But the definitions are tighter. The scope is broader. And the intent is clear: MDR classifies devices based on risk more aggressively than MDD did.

The shift was deliberate. Regulators identified gaps in the MDD classification system where devices with significant patient risk were under-classified. MDR corrected those gaps. The result is that certain device types, certain indications, and certain modes of action now sit one class higher.

The most common upclassifications I see involve:

• Devices used in direct contact with the heart or central circulatory system
• Implantable devices, even short-term ones
• Devices delivering medicines or substances to the body
• Software that drives or influences treatment decisions
• Devices intended for self-testing or near-patient testing

If your device touches any of these categories, you need to re-examine your classification under MDR rules. Not the rules you remember from MDD. Not the rules from your legacy technical file. The current MDR Annex VIII rules.

The Rules That Trap Most Manufacturers

Let me walk through the rules that most often drive upclassification. These are not obscure edge cases. These are mainstream devices that manufacturers assumed would remain in the same class.

Rule 5: Invasive Devices in Body Orifices

Under MDD, many devices used in body orifices were Class I or IIa, depending on duration and location. Under MDR, Rule 5 pulls more devices into IIa and IIb. The key change is how “surgically invasive” is interpreted and how contact duration is defined.

Devices used in the oral cavity beyond the pharynx, devices in the ear canal beyond the eardrum, or nasal devices that reach the nasopharynx now face stricter classification. If the device is intended for short-term use (less than 60 minutes) it may stay IIa. But if it is reusable, or if duration extends beyond 60 minutes, you are looking at IIb.

I reviewed a nasal airway device last year that the manufacturer had classified as Class I under MDD. Under MDR Rule 5, it was IIa because it was used continuously for several hours. The manufacturer had not updated their classification rationale. The Notified Body flagged it immediately.

Rule 8: Software

This is where the most confusion sits. Rule 8 in MDR Annex VIII classifies software based on the severity of the clinical decision it drives. The rule uses three categories: monitoring, diagnosis, and prediction or treatment.

Software that monitors physiological processes where the nature of variations could result in immediate danger to the patient is Class IIb. Software intended to provide information used to make decisions with diagnosis or therapeutic purposes is Class IIa. Software intended for such purposes where decisions could cause death or irreversible deterioration is Class IIb.

Many software devices that were Class I under MDD are now IIa or IIb under MDR. The threshold is not whether the software acts autonomously. The threshold is whether the information it provides directly influences clinical decisions that could harm the patient if wrong.

I worked with a team developing a clinical decision support tool for radiology. They believed it was Class I because it only provided recommendations to the clinician. Under Rule 8, it was Class IIa because those recommendations directly influenced diagnostic decisions. When we examined the failure modes—what happens if the algorithm is wrong—it became clear the risk was higher than they assumed.

Rule 11: Active Therapeutic Devices Administering or Exchanging Energy

Devices that deliver energy to the body for therapeutic purposes are generally Class IIa. But if the energy is delivered in a potentially hazardous way—considering the nature, density, and site of application—the device moves to Class IIb.

This rule affects electrotherapy devices, ultrasound therapy devices, and light-based treatment devices. The question is not just whether energy is delivered. The question is whether that energy could cause harm if applied incorrectly, and whether the device design adequately controls that risk.

A neurostimulation device I reviewed was classified as IIa by the manufacturer. When we examined the intended site (spinal cord) and the energy characteristics, it became clear that the potential for harm put it in IIb territory. The manufacturer had focused on the therapeutic mechanism, not on the hazard profile.

Rule 15: Contraceptive or STI Prevention Devices

Devices intended to prevent pregnancy or the transmission of sexually transmitted infections are Class IIb if they are implantable or long-term invasive. They are Class III if they are also intended for STI prevention.

Under MDD, some of these devices sat in Class IIa. Under MDR, the classification reflects the potential consequences of failure. If a contraceptive device fails, the outcome is pregnancy—an outcome with significant health, social, and economic implications. MDR treats that failure mode as higher risk than MDD did.

What Upclassification Means for Your Clinical Evaluation

Now comes the part that matters for the work you do daily. If your device moved from Class IIa to Class IIb, the clinical evaluation requirements change. Not slightly. Fundamentally.

For Class IIb devices, MDCG 2020-5 and MDCG 2020-6 require a more robust demonstration of clinical safety and performance. The depth of literature review increases. The appraisal of clinical data must be more critical. The justification for equivalence claims becomes stricter. And the requirements for clinical investigations shift.

Under MDR, Class IIb devices face higher scrutiny on clinical investigation requirements. If you claim equivalence, the equivalence must be technically and clinically valid under stricter criteria. If you rely on literature, the literature must be sufficient to demonstrate both safety and performance for your specific device and indication. If neither equivalence nor literature is sufficient, you need clinical investigation data.

I worked on a file where the device was upclassified from IIa to IIb. The clinical evaluation had been built on a combination of equivalence and literature. When we re-assessed under IIb requirements, the equivalence claim no longer held because the predicate device was not sufficiently similar. The literature was extensive but did not cover the specific patient population. The Notified Body requested a clinical investigation. The manufacturer had not budgeted for it. The timeline collapsed.

The PMCF Obligation Also Changes

Post-market clinical follow-up is mandatory for implantable devices and Class III devices. For Class IIb devices, PMCF is also expected, though the intensity and structure may differ.

If your device moved from IIa to IIb, your PMCF plan must reflect that. The methods must be more proactive. The data collection must be more structured. The triggers for review and action must be tighter.

I see PMCF plans that were written for Class IIa devices and then simply relabeled when the device was upclassified. The content does not change. The plan still describes passive complaint monitoring and periodic literature reviews. That is not sufficient for a Class IIb device, especially one with limited pre-market clinical data.

If you are building a PMCF plan for a newly upclassified IIb device, the plan should address how you will actively collect clinical performance data post-market. That may include registries, structured follow-up protocols, or post-market clinical studies. It is not optional. It is part of demonstrating ongoing compliance with safety and performance requirements.

How to Verify Your Classification Is Correct

The most reliable way to verify classification is to apply all rules in MDR Annex VIII systematically. Do not stop at the first rule that fits. Apply every rule. Document which rules apply, which do not, and why. Then select the highest classification that results from any applicable rule.

MDCG 2021-24 provides detailed guidance on the application of classification rules. It includes worked examples and clarifications on ambiguous cases. Use it. The guidance was written specifically to reduce classification errors.

If you are unsure whether your device moved classes, ask your Notified Body early. Do not wait until submission. A pre-submission meeting or a classification opinion can clarify the path forward before you invest in clinical data generation.

One more thing. If your device was already certified under MDD and you are transitioning to MDR, do not assume the classification stays the same. The transition does not grandfather the old classification. You must reclassify under MDR rules. And if the class changes, your technical file and clinical evaluation must reflect that.

What This Means for Your Submission Strategy

If you discover your device is upclassified during the transition to MDR, the first step is to assess the gap. Compare what you have in your current technical file to what MDR requires for the new class. Look at clinical data, risk management, design verification, and post-market surveillance.

The gap is usually widest in clinical evaluation. If you built your clinical evidence base for Class IIa and the device is now IIb, you may need additional data. That data may come from expanded literature review, from clinical investigations, or from structured post-market studies.

The second step is to adjust your timeline. Upclassification delays certification. There is no way around it. If you need to generate new clinical data, that takes time. If you need a more extensive clinical evaluation report, that takes time. If you need Notified Body input on classification or clinical strategy, that takes time.

Do not try to hide the upclassification or minimize it in the submission. The Notified Body will identify it. They are trained to catch classification errors. When they do, the entire submission slows down while you correct the foundation.

I have seen teams try to argue that their device should remain in the lower class because it was always Class IIa under MDD. That argument does not work. The Notified Body applies MDR rules. They do not negotiate. If the device is IIb under current rules, it is IIb. The faster you accept that and adjust your submission, the faster you move forward.

Final Thoughts on Upclassification

Upclassification under MDR is not a bureaucratic inconvenience. It is a reflection of how regulators now assess risk. The devices that moved up in class are the ones where pre-market oversight was insufficient under MDD. MDR corrected that.

For you as a regulatory or clinical affairs professional, upclassification means more work. More data. More documentation. More scrutiny. But it also means a clearer framework. The classification rules in MDR are more explicit than they were under MDD. If you apply them correctly, you know where you stand.

The mistake is assuming that because a device was always Class IIa, it will remain Class IIa. Classification is not based on history. It is based on the current rules and the current understanding of risk. If you are working on a device that transitioned from MDD to MDR, or if you are developing a new device under MDR, start with classification. Get it right. Document it thoroughly. Then build everything else on that foundation.

If you get classification wrong, everything downstream is wrong. The clinical evaluation is scoped incorrectly. The conformity assessment route is wrong. The post-market obligations are incomplete. And the Notified Body will send you back to square one.

That is the reality. Classification is not a formality. It is the first and most important regulatory decision you make.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.

Reclassification to Class IIb increases clinical evidence requirements and associated costs. See our detailed breakdown of CE marking costs for medical devices.